Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BSD gets breast cancer therapy patent from Duke:

This article was originally published in Clinica

Executive Summary

BSD Medical has signed an exclusive patent licence agreement for rights to Duke University's hyperthermia treatment for primary breast cancer. The Salt Lake City, Utah-based firm intends to integrate the technology with its current BSD-2000 and BSD-500 hyperthermia systems. The treatment will be used to complement radiation therapy, chemotherapy and heat-released, targeted liposome drug delivery. BSD claims that the potential to treat breast cancer with hyperthermia therapy has been boosted by trials at the Durham, North Carolina university. Studies have shown that patients receiving radiation therapy in conjunction with hyperthermia have a greater chance of complete response compared with those receiving radiotherapy alone.

You may also be interested in...



Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel